Inventor · disambiguated record
Emma Masteller
Also filed as: MASTELLER EMMA
12 granted patents·11 pending applications·62 citations·filing 2005–2022
89Inventor score
Top patents by PatentIndex Score
23 records- 0195US11155615B2Anti-ROR1 antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Oct 26, 2021·13 cites·13 claims
- 0295US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0392US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0488US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 0583US7722862B2Regulatory T cells suppress autoimmunityUNIV CALIFORNIA·Filed 2006·Granted May 25, 2010·3 cites·9 claims
- 0681US10221243B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Mar 5, 2019·4 cites·23 claims
- 0781US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0874US10982001B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 20, 2021·1 cites·17 claims
- 0971US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 1068US10822421B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Nov 3, 2020·0 cites·37 claims
- 1166US10975153B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Apr 13, 2021·1 cites·29 claims
- 1266US2021277130A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1365US2023192870A1Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1464US2021107986A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1564US2014079699A1Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)FIVE PRIME THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 1662US11559583B2Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·0 cites·18 claims
- 1759US11421034B2Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancerFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 23, 2022·0 cites·15 claims
- 1858US2013302322A1Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)FIVE PRIME THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 1957US2021317219A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2052US2005186207A1Regulatory T cells suppress autoimmunityUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 2151US2018085472A1Combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2246US2010310588A1Regulatory t cells suppress autoimmunityUNIV CALIFORNIA·Filed 2010·Application pending·0 cites
- 2338US2018147271A1Anti-ror1 chimeric antigen receptorsBLUEBIRD BIO INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Emma Masteller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →